Trial Profile
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 26 Jun 2014 New trial record